Nyxoah S.A., a Mont-Saint-Guibert, Belgium-based medical device company focused on developing a neurostimulation based therapy for patients suffering from Obstructive Sleep Apnea (OSA), raised €18m in funding.
The round was led by Gilde Healthcare with participation from SRIW and existing shareholders. In addition, Novallia has provided a subordinated loan.
The company will use the funds to bring its lead product to market the BLAST OSA international study, CE Mark approval and the US FDA approval process.
Led by newly appointed CEO Enrique Vega, an experienced senior executive with a track record in the Cardiac Rhythm Management, Sleep Apnea and Neurostimulation fields, Nyxoah focuses on developing and commercializing a neurostimulation based therapy for the treatment of Obstructive Sleep Apnea (OSA). Its lead-free neurostimulator is said to be capable of delivering bilateral hypoglossal nerve stimulation for moderate to severe OSA patients, who have failed conventional CPAP therapy.